Evotec AG: Release according to Article 26, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
December 13, 2017 at 08:45 pm IST
Share
DGAP Voting Rights Announcement: Evotec AG
Evotec AG: Release according to Article 26, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
13.12.2017 / 16:12
Dissemination of a Voting Rights Announcement transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
Notification of Major Holdings
1. Details of issuer
Evotec AG
Manfred Eigen Campus / Essener Bogen 7
22419 Hamburg
Germany
2. Reason for notification
Acquisition/disposal of shares with voting rights
X
Acquisition/disposal of instruments
Change of breakdown of voting rights
Other reason:
3. Details of person subject to the notification obligation
Name:
City and country of registered office:
The Goldman Sachs Group, Inc.
Wilmington, Delaware United States of America (USA)
4. Names of shareholder(s)
holding directly 3% or more voting rights, if different from 3.
5. Date on which threshold was crossed or reached:
06 Dec 2017
6. Total positions
% of voting rights attached to shares (total of 7.a.)
% of voting rights through instruments (total of 7.b.1 + 7.b.2)
total of both in % (7.a. + 7.b.)
total number of voting rights of issuer
Resulting situation
0.44 %
4.39 %
4.83 %
147520005
Previous notification
0.49 %
4.56 %
5.05 %
/
7. Notified details of the resulting situation a. Voting rights attached to shares (Sec.s 21, 22 WpHG)
ISIN
absolute
in %
direct (Sec. 21 WpHG)
indirect (Sec. 22 WpHG)
direct (Sec. 21 WpHG)
indirect (Sec. 22 WpHG)
DE0005664809
652286
%
0.44 %
Total
652286
0.44 %
b.1. Instruments according to Sec. 25 para. 1 No. 1 WpHG
Type of instrument
Expiration or maturity date
Exercise or conversion period
Voting rights absolute
Voting rights in %
Securities Lending
Open
6479181
4.39 %
Total
6479181
4.39 %
b.2. Instruments according to Sec. 25 para. 1 No. 2 WpHG
Type of instrument
Expiration or maturity date
Exercise or conversion period
Cash or physical settlement
Voting rights absolute
Voting rights in %
%
Total
%
8. Information in relation to the person subject to the notification obligation
Person subject to the notification obligation is not controlled and does itself not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer (1.).
X
Full chain of controlled undertakings starting with the ultimate controlling natural person or legal entity:
Name
% of voting rights (if at least held 3% or more)
% of voting rights through instruments (if at least held 5% or more)
Total of both (if at least held 5% or more)
The Goldman Sachs Group, Inc.
%
%
%
Goldman Sachs (UK) L.L.C.
%
%
%
Goldman Sachs Group UK Limited
%
%
%
Goldman Sachs International
%
%
%
The Goldman Sachs Group, Inc.
%
%
%
Goldman Sachs & Co. LLC
%
%
%
The Goldman Sachs Group, Inc.
%
%
%
GSAM Holdings LLC
%
%
%
Goldman Sachs Asset Management, L.P.
%
%
%
Goldman Sachs Asset Management International Holdings L.L.C.
%
%
%
Goldman Sachs Asset Management Co., Ltd.
%
%
%
9. In case of proxy voting according to Sec. 22 para. 3 WpHG
Date of general meeting:
Holding position after general meeting:
% (equals voting rights)
10. Other explanatory remarks:
13.12.2017 The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de
Evotec SE is a Germany-based drug discovery and development company. The company is engaged in development of new pharmaceutical products through research alliances and development partnerships with pharmaceutical and biotechnology companies, academic institutions, patient organizations and venture capital companies. The drug discovery solutions are provided in the form of fee-for-service work, integrated drug discovery alliances, development partnerships, licensing of drug candidates and consulting arrangements. Evotec SE operates in a number of areas, including neuroscience, diabetes and complications of diabetes, pain and inflammation, oncology, infectious diseases, respiratory diseases and fibrosis. Its pipeline covers a range of therapeutic areas, such as CNS Insomnia, Chronic cough, immunology & inflammation, womenâs health endometriosis, nephrology, dermatological diseases, fibrotic disease and antiviral, among others.